- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ImaRx agent completes phase I trials
A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx
A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx claims may be able to significantly enhancegray-scale ultrasound scans in cardiac, blood pool, kidney andliver imaging.
MRX-115 Aerosomes consists of sterile phospholipid-coated microbubbleswith a mean diameter of 2.5 microns. ImaRx plans to use the Aerosomestechnology to develop targeted, site-specific agents for imagingand drug delivery for lymph nodes and diseased tissue.
ImaRx said the phase I trials gave positive results for useof MRX-115 in myocardial perfusion imaging and indicated thatthe agent has a wide safety profile relative to the dose neededfor clinical efficacy. Phase II trials will begin later this year,and ImaRx plans to pursue additional indications for MRX-115 suchas imaging of liver and kidney perfusion.
ImaRx is the developer of SonoRx, an oral ultrasound contrastagent for abdominal imaging under license to Bracco Diagnostics(SCAN 7/27/94 and 3/10/93).
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
